The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy

Alessandro Armuzzi, Gionata Fiorino, Angela Variola, Natalia Manetti, Walter Fries, Ambrogio Orlando, Giovanni Maconi, Fabrizio Bossa, Maria Cappello, Livia Biancone, Laura Cantoro, Francesco Costa, Renata D'Incà, Paolo Lionetti, Mariabeatrice Principi, Fabiana Castiglione, Maria L. Annunziata, Antonio Di Sabatino, Maria Di Girolamo, Maria M. TerpinClaudio C. Cortelezzi, Simone Saibeni, Arnaldo Amato, Sandro Ardizzone, Luisa Guidi, Silvio Danese, Arianna Massella, Agostino Ventra, Giulia Rizzuto, Alessandro Massari, Francesco Perri, Vito Annese, Silvia Saettone, Roberto Tari, Carlo Petruzzellis, Gianmichele Meucci, Gianni Imperiali, Francesco W. Guglielmi, Silvia Mazzuoli, Luigi Caserta, Maria Caterina Parodi, Agostino Colli, Anna Ronchetti, Daniela Pugliese, Andrea Geccherle, Francesca Rogai, Stefano Milani, Sara Renna, Andrea Cassinotti, Angelo Andriulli, Giuseppina Martino, Barbara Scrivo, Edoardo Troncone, Anna Kohn, Lorenzo Bertani, Greta Lorenzon, Silvia Ghione, Olga Nardone, Maurizio Vecchi, Angela Bertani, Matteo A. Bosani, Cristina Bezzio, Raffaele Salerno

Research output: Contribution to journalArticle

25 Citations (Scopus)


Background: We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. Methods: A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Results: Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. Conclusions: In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.
Original languageEnglish
Pages (from-to)568-579
Number of pages12
JournalInflammatory Bowel Diseases
Publication statusPublished - 2019


  • Adolescent
  • Adult
  • Antibodies, Monoclonal
  • Biosimilar
  • CT-P13
  • Crohn's disease
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents
  • Humans
  • Inflammatory Bowel Diseases
  • Inflammatory bowel disease
  • Inflectra
  • Infliximab
  • Italy
  • Male
  • Prognosis
  • Prospective Studies
  • Remsima
  • Ulcerative colitis
  • Young Adult


Dive into the research topics of 'The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy'. Together they form a unique fingerprint.

Cite this